Samsung Biologics Strikes $1.8 Billion Deal for Swiss Peptide Maker PolyPeptide Group

On Monday, July 20, 2026, Samsung Biologics announced a cash offer that would take Swiss‑based PolyPeptide Group private for 1.46 billion Swiss francs – roughly US$1.8 billion at current rates. The price translates to 44.31 CHF per share, a modest premium that lifted PolyPeptide’s stock about 5.3 % in early trade.

PolyPeptide, headquartered in the quiet town of Baar, Switzerland, has made a name for itself as a specialist in peptide‑based active pharmaceutical ingredients. Its catalogue now spans more than a thousand therapeutic peptides, many of which underpin next‑generation obesity and diabetes medicines, especially the high‑profile GLP‑1 class.

For Samsung Biologics, the move is a clear pivot. Until now the South Korean company has built a formidable reputation as a contract‑development‑and‑manufacturing organization (CDMO) focused largely on large‑molecule biologics like antibodies. By snatching up PolyPeptide, Samsung is sprinting into the peptide arena, a space that investors have been flagging as a growth hot‑spot, especially after the surge in demand for weight‑loss drugs.

“After a comprehensive review of strategic options, the Board is convinced that Samsung Biologics’ offer is compelling for our shareholders, delivering an attractive cash price and immediate, certain value today,” said Peter Wilden, chairman of PolyPeptide Group, in a statement released alongside the tender offer.

The acquisition also bolsters Samsung’s geographic footprint. PolyPeptide already operates sites across Europe and the United States, and its recent expansions into India add a new manufacturing hub to Samsung’s global network.

From a market‑watch perspective, the deal is being billed as the largest biopharma M&A ever recorded in South Korea. While Samsung’s own shares slipped roughly 3.6 % after the news – likely reflecting the sizeable cash outlay – analysts see the long‑term upside as the company diversifies its pipeline and taps into a lucrative market segment.

Regulatory approval and a shareholder vote are still required, and the parties have pencilled in a closing window that runs to the end of 2026. No exact date has been set, but both sides are signaling confidence that the paperwork will be wrapped up before the year wraps.